Tweet
Respir Med Case Rep
. 2024 Oct 18:52:102131.
doi: 10.1016/j.rmcr.2024.102131. eCollection 2024. Persistent SARS-CoV-2 infection resolved after B-cell recovery in a patient with follicular lymphoma treated with B-cell depletion therapy
Yuriko Sueda 1 , Hirokazu Tokuyasu 1 , Momoka Atsuta 1 , Hiromitsu Sakai 1 , Katsunori Arai 1 , Chika Esumi 2 , Misato Mochizuki 3 , Tomoki Itohara 4 , Naoki Fujisawa 5 , Akira Yamasaki 6
Affiliations
A 68-year-old woman with follicular lymphoma was treated with chemotherapy, including the anti-CD20 monoclonal antibody obinutuzumab, and achieved remission. A month after the administration of obinutuzumab, the patient contracted coronavirus disease 2019 (COVID-19), and various antiviral drugs were administered. However, the infection had not been eliminated. One year and three months after chemotherapy, peripheral B cell recovery was achieved, and the infection had resolved. This report provides insight into the course of COVID-19 in patients with impaired humoral immunity.
Keywords: Anti-CD20 antibody; B-cell depletion therapy; Follicular lymphoma; Obinutuzumab; Persistent SARS-CoV-2 infection.
. 2024 Oct 18:52:102131.
doi: 10.1016/j.rmcr.2024.102131. eCollection 2024. Persistent SARS-CoV-2 infection resolved after B-cell recovery in a patient with follicular lymphoma treated with B-cell depletion therapy
Yuriko Sueda 1 , Hirokazu Tokuyasu 1 , Momoka Atsuta 1 , Hiromitsu Sakai 1 , Katsunori Arai 1 , Chika Esumi 2 , Misato Mochizuki 3 , Tomoki Itohara 4 , Naoki Fujisawa 5 , Akira Yamasaki 6
Affiliations
- PMID: 39507269
- PMCID: PMC11538806
- DOI: 10.1016/j.rmcr.2024.102131
A 68-year-old woman with follicular lymphoma was treated with chemotherapy, including the anti-CD20 monoclonal antibody obinutuzumab, and achieved remission. A month after the administration of obinutuzumab, the patient contracted coronavirus disease 2019 (COVID-19), and various antiviral drugs were administered. However, the infection had not been eliminated. One year and three months after chemotherapy, peripheral B cell recovery was achieved, and the infection had resolved. This report provides insight into the course of COVID-19 in patients with impaired humoral immunity.
Keywords: Anti-CD20 antibody; B-cell depletion therapy; Follicular lymphoma; Obinutuzumab; Persistent SARS-CoV-2 infection.